PIK3CA and neoplasm: In pre-clinical models, combinations of PI3K and MEK inhibitors have consistently shown improved efficacy compared to either single agent alone, causing striking regressions in some cases, in a range of human tumour xenograft and mouse models [6], [12], [17], [18], [19].